|
Title |
Amalaki rasayana and max HB in sickle cell anaemia: An open label non-comparative clinical trial
|
|
Authors |
Amit Nampalliwar1,* & Pallavi Roy2
|
|
Affiliation |
1Department of Rog Nidan evum Vikriti Vigyan (Pathology), Government Ayurveda College and Hospital, Bilaspur-495001, Chhattisgarh, India; 2Department of Dravyaguna (Materia Medica & Pharmacology), Shri N.P.A. Government Ayurveda College and Hospital, Raipur-492001, Chhattisgarh, India; *Corresponding author
|
|
|
Amit Nampalliwar - E-mail: dr.n.amitkumar@gmail.com;
Phone: +91 9930394087 |
|
Article Type |
Research Article
|
|
Date |
Received October 1, 2026; Revised October 31, 2026; Accepted October 31, 2026, Published October 31, 2026
|
|
Abstract |
Sickle cell anaemia is an inherited hemoglobin disorder characterized by sickling of red blood cells, leading to vaso-occlusion, chronic anaemia and recurrent systemic complications. Therefore, it is of interest to evaluate the clinical efficacy of Amalaki Rasayana and Capsule Max HB in the management of sickle cell anaemia. An open-label, non-comparative clinical trial was conducted on 25 patients at Government Ayurveda College and Hospital, Bilaspur, Chhattisgarh, with outcomes assessed over 60 days using the Dutch-AIMS2-HFF Symptoms Severity Scale, Wilcoxon Signed Rank Test and paired t-test. Treatment produced significant improvements in subjective symptoms, including anaemia (35.71%), pallor (43.40%), bodyache (37.50%), palpitation (43.86%), hand-foot syndrome (25.58%), loss of appetite (41.18%) and recurrent respiratory infection (37.78%), with an overall improvement of 37.86%, alongside increases in Hb, RBC, MCH, MCV and MCHC. Thus, combined Amalaki Rasayana and Capsule Max HB therapy showed clinically meaningful improvement in symptomatic and hematological parameters, supporting its potential as an adjunctive Ayurvedic intervention for sickle cell anaemia. |
|
Keywords |
Sickle cell anaemia, sannipataja pandu, Amalaki Rasayana, capsule max hb, Amalaki Rasayana, giloy satva, ayurveda clinical trial
|
|
Citation |
Nampalliwar et al. Bioinformation 22(10): 7409-7414 (2026)
|
|
Edited by |
Ritik Kashwani
|
|
ISSN |
0973-2063
|
|
Publisher |
|
|
License |
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
|
|
|
|